INO vs PGEN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INO and PGEN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INO and PGEN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Inovio Pharmaceuticals is a clinical-stage biotechnology company built around a DNA medicines platform. The idea is to design small circular DNA molecules, called plasmids, that instruct a patient's own cells to produce specific proteins that target disease, and to deliver those plasmids using Inovio's proprietary CELLECTRA device rather than viral vectors or lipid nanoparticles. The company's most advanced program is INO-3107, an immunotherapy for recurrent respiratory papillomatosis (RRP), a rare condition in which HPV-driven benign tumors recur in the airway and often require repeated surgeries. Inovio's broader pipeline has historically centered on HPV-related diseases, including head and neck cancer (INO-3112) and cervical dysplasia (VGX-3100, whose US development was discontinued in 2023 while a partner pursues it in China).

Full INO guide

Precigen, Inc. is a Maryland-based biopharmaceutical company that develops precision medicines using its proprietary gene- and cell-therapy platforms, most notably the AdenoVerse gorilla-adenovector system. For years it was a clinical-stage, cash-burning research company (formerly Intrexon), but in August 2025 it earned full FDA approval for Papzimeos (zopapogene imadenovec, formerly PRGN-2012), the first approved immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV 6 and 11 in which benign tumors recur in the airway and typically require repeated surgeries. Papzimeos is given as four subcutaneous injections over roughly 12 weeks and is designed to trigger an immune response against HPV-infected cells. Precigen also runs Exemplar, a small research-models and services business.

Full PGEN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• INO drivers: INO-3107 FDA decision for RRP; DNA medicines platform validation.
• PGEN drivers: Papzimeos launch ramp; Path to cash-flow break-even.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is binary clinical and regulatory outcome: the stock is tightly bound to the INO-3107 FDA decision, and rejection, a delay, or a request for more data could sharply reduce the company's value. For PGEN, pGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once.

Pick INO if you believe its drivers more; PGEN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INO and PGEN guides.

INO. Standard valuation multiples do not apply here: Inovio is pre-revenue and unprofitable, so metrics like P/E are meaningless and the equity is effectively an option on a small number of clinical and regulatory outcomes. Value is driven by the probability and timing of an INO-3107 approval, the cash runway, and dilution, not by earnings. Verify the latest cash position, share count, and program status before acting, as they can change quickly.

PGEN. Precigen transitioned to commercial stage with the 2025 FDA approval of Papzimeos, and Q1 2026 revenue of about $23.3 million came almost entirely from that launch versus roughly $1.3 million a year earlier. Because trailing revenue is still small relative to a roughly $2 billion market cap, conventional multiples are not meaningful and the stock trades on forward launch expectations. Management targets cash-flow break-even by the end of 2026, funded by cash on hand plus expected Papzimeos sales.

Headline figures (approximate, Jul 2026): INO shows revenue Effectively none; pre-revenue with no approved product on the market, profitability status Not profitable; sustained operating losses funded by capital raises, cash runway Management guided into roughly early 2027, near the target FDA decision, lead program stage INO-3107 (RRP) BLA under FDA review; target decision date around late Oct 2026; PGEN shows stock price ~$5.64 (Jul 2026), market cap ~$2.0B, shares outstanding ~356.5M, revenue (q1 2026) ~$23.3M total (~$21.6M Papzimeos).

INO and PGEN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined INO and PGEN exposure against your real portfolio. It is not an investment adviser.